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Background and objectives: Tumor necrosis factor (TNF)-inhibitors are used to treat psoriatic arthritis
(PsA), but only a limited number of observational studies on this subject have been published thus far.
The aim of this research was to analyze the effectiveness and drug survival of TNF-inhibitors in the
treatment of PsA.
Methods: PsA patients identified from the National Register for Biologic Treatment in Finland (ROB-FIN)
starting their first, second, or third TNF-inhibitor treatment between 2004 and 2014 were included.
Effectiveness was measured using ACR and EULAR response criteria and modeled using ordinal logistic
regression. Treatment persistence was analyzed using Kaplan–Meier survival analysis and Cox propor-
tional hazards model.
Results: The study comprised 765 patients and 990 TNF-inhibitor treatment courses. EULAR moderate
treatment responses at 6 months were achieved by 68% and 37% of the users of the first and the second
or the third biologic, respectively. The probabilities of discontinuing the treatment within 12 and 24
months were 20% and 28%, respectively. Adjusted treatment responses to all TNF-inhibitors were similar;
however, co-therapy with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)
was not associated with better effectiveness. Adalimumab [hazard ratio (HR) ¼ 0.62; 95% confidence
interval (CI): 0.44–0.88] was superior to infliximab in drug survival while etanercept (HR ¼ 0.77, 95% CI:
0.55–1.1) and golimumab (HR ¼ 0.75, 95% CI: 0.46–1.2) did not differ from it. Co-medication with
csDMARDs did not statistically improve drug survival.
Conclusion: All available TNF-inhibitors showed similar treatment responses with or without csDMARDs.
Adalimumab was associated with better drug survival when compared to infliximab.
& 2017 Elsevier Inc. All rights reserved.Introduction
In psoriatic arthritis (PsA) patients with peripheral arthritis and
inadequate response to at least one conventional synthetic disease-altonen).modifying anti-rheumatic drugs (csDMARDs)-intensified treatment
with biological DMARDs (bDMARDs), usually TNF-inhibitors are war-
ranted [1]. A number of randomized controlled trials on the efficacy
and safety of TNF-inhibitors in the treatment of PsA have been
published and their pooled results suggest that TNF-inhibitors are
both an effective and relatively safe therapy for PsA [2]. Several
observational studies on the effectiveness and drug survival of TNF-
inhibitors in PsA, based on patient registries Denmark, Norway,
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studies, proportions of patients reaching good EULAR response at
6 months have ranged from 38 to 55 with no statistically significant
association to concomitant methotrexate (MTX) therapy. Overall, 12–
30% of patients have discontinued their treatment within 1 year while
male sex, higher CRP levels, and concomitant therapy with MTX use
have been associated with improved drug survival. A recent systematic
review found that combination therapy with MTX does not improve
efficacy or safety of TNF-inhibitors [11].
The aim of the present study was to describe the treatment
response and long-term survival on TNF-inhibitors in PsA and to
analyze whether the choice of TNF-inhibitor or concomitant
csDMARD or glucocorticoid therapy affects these outcomes.Patients and methods
Patients
The National Register for Biologic Treatment in Finland (ROB-
FIN) was established in 1999 as a nationwide register to monitor
long-term effectiveness and safety of biological therapies in the
treatment of rheumatic diseases. Data are collected during speci-
alized healthcare routine visits that usually occur 3 and 6 months
after beginning of treatment and then semiannually or annually
afterward. Data to be collected include information on patients’
demographics, concurrent anti-rheumatic medication use, and
disease activity including the number of swollen (0–54 and 0–
28) and tender joints (0–53 and 0–928), patient-reported out-
comes, and laboratory assessments (Table 1). Data collection is
carried out using paper data collection forms and more recently,
an electronic patient monitoring software (GoTreatIT, DiaGraphIT
(Kristiansand, Norway) is the company that develops GoTreatIT
software). Additional data on patients’ hospital treatment andTable 1
Patient characteristics and medication at the baseline of TNF-inhibitor therapy [median
Variable First bDMARD Seco
Age 49 (41–56) 51
Men 55% (366) 46%
Patient global (VAS 0–100) 48 (23–68) 38
Pain (VAS 0–100) 51 (30–70) 37
Investigator global (VAS 0–100) 29 (12–46) 20
HAQ 0.75 (0.25–1.2) 0.79
ESR 12 (6.0–24) 11
CRP 6.0 (3.0–14) 5.0
Years from diagnosis 5.0 (0.96–12) 9.0
SJC 1.0 (0–5.0) 1.0
TJC 2.0 (0–7.0) 1.0
TJC28 1.0 (0–3.0) 0
SJC28 1.0 (0–4.0) 0
DAS28 3.1 (2.1–4.3) 2.6
Year of treatment onset 2009 (2006–2011) 2011
Outpatient visits in the past 2 y 2.0 (0–8.0) 3.0
Hospital days in the past 2 y 0 (0–4.0) 0
Adalimumab 38% (254) 44%
Etanercept 39% (258) 34%
Infliximab 18% (120) 6.2%
Golimumab 5.4% (36) 16%
Methotrexate 53% (356) 51%
Sulfasalazine 20% (130) 12%
Leflunomide 11% (70) 7.1%
Ciclosporin 6.9% (46) 4.6%
Hydroxychloroquine 4.1% (27) 4.6%
Any csDMARD 75% (501) 67%
Oral glucocorticoids 27% (181) 34%
csDMARD ¼ conventional synthetic disease-modifying anti-rheumatic drug; CRP ¼ C-re
ESR ¼ erythrocyte sedimentation rate; HAQ ¼ Health Assessment Questionnaire; TJC ¼outpatient specialized healthcare visits prior to TNF-inhibitor
therapy onset for reasons other than ICD10 M-class were retrieved
from the National Care Register for Health Care.
Patients clinically diagnosed with PsA and starting TNF-
inhibitor therapy as their first, second, or third bDMARD between
2004 and 2014 were included in this study. Individuals were
excluded from effectiveness analysis if biologic therapy had been
initiated before the baseline visit or treatment onset was delayed
more than 6 months after the baseline visit. All patients were
included in the drug survival analysis, but information on avail-
ability of the baseline visit was used as a potential confounding
factor. Only patients using adalimumab, etanercept, golimumab, or
infliximab were included in this study. Follow-up data on included
patients were available until the end of 2015.
Analysis
Disease Activity Score based on 28 joints (DAS28) was calculated
using four variables including erythrocyte sedimentation rate (ESR)
while remission was defined as DAS28 o 2.6 [12]. Effectiveness was
measured using both ACR and EULAR treatment response criteria [13–
15]. Treatment response and remission rates at time points of 3, 6, 12,
and 24 months were estimated using linear interpolation. LUNDEX-
correction was applied to the results by multiplying the proportion of
patients achieving response by the proportion of patients still on
treatment [16]. The proportion of patients discontinuing treatment
was evaluated using Kaplan–Meier survival analysis. Follow-up in
survival analysis was truncated at 36 months.
Baseline differences were tested using Kruskal–Wallis and chi-
squared tests for continuous and categorical variables, respectively.
Univariate and multivariate ordinal logistic regression were used
to identify any predictors affecting the clinical response. Non-
responder imputation, in which all patients having discontinued
their treatment or been lost to follow-up were considered non-(IQR)/% (N)]
nd or third bDMARD Total Missing %
(43–58) 50 (41–57) 0
(149) 52% (515) 0
(14–63) 46 (19–66) 9.7
(17–66) 48 (23–68) 7.0
(9.0–32) 25 (10–42) 20
(0.25–1.2) 0.75 (0.25–1.2) 17
(6.0–23) 12 (6.0–24) 12
(3.0–12) 5.0 (3.0–13) 11
(3.9–15) 6.1 (1.7–13) 0
(0–2.0) 1.0 (0–4.0) 19
(0–4.0) 2.0 (0–6.0) 20
(0–2.0) 1.0 (0–3.0) 8.7
(0–2.0) 0 (0–3.0) 5.2
(1.8–3.8) 2.9 (1.9–4.1) 30
(2007–2013) 2009 (2007–2012) 0
(1.0–11) 3.0 (0–8.0) 0
(0–4.0) 0 (0–4.0) 0
(143) 40% (397) 0
(108) 37% (366) 0
(20) 14% (140) 0
(51) 8.8% (87) 0
(165) 53% (520) 0
(39) 17% (169) 0
(23) 9.4% (93) 0
(15) 6.2% (61) 0
(15) 4.2% (42) 0
(217) 73% (718) 0
(110) 29% (291) 0
active protein (mg/l); DAS28 ¼ Disease Activity Score based on 28-joint assessment;
tender joint count; SJC ¼ swollen joint count; VAS ¼ Visual Analog Scale.
K. Aaltonen et al. / Seminars in Arthritis and Rheumatism 46 (2017) 732–739734responders, was undertaken as a sensitivity analysis. This was
equivalent to LUNDEX-correction at group-level. Drug persistence
was analyzed using a Cox proportional hazards (PH) model with age,
csDMARD, and corticosteroid use as time-dependent covariates. The
proportional hazards assumption was tested for each variable and
for the model in general. As the said assumption was violated for
golimumab, the results were also separately analyzed for the first 6
months of follow-up and for the remaining follow-up period by
including an interaction term with time in the model. A stepwise
model selection based on Akaike information criteria (AIC) was used
to identify the best model in each of the multivariate analysis. Effect
modification between different TNF-inhibitors and csDMARD or
glucocorticoid use was tested by including the appropriate inter-
action terms in the model. Missing data at baseline and follow-up
visits were imputed by multiple imputation using predictive mean
matching and 10 imputed data sets. The descriptive results are
reported as medians with interquartile ranges (IQR) or percentages
while the results of the regression analyses are reported either as
proportional odds ratios (pOR) or hazard ratios (HR) with their
respective 95% confidence intervals (95% CI). The data were analyzed
using R statistical programming language version 3.2.1 (R foundation
for statistical computing, Vienna, Austria).
Favorable ethical board statement was granted by the Helsinki
and Uusimaa Hospital District coordinating ethical committee
while the study permission was obtained from the National
Institute for Health and Welfare.Results
Patients
Of the 852 PsA patients identified from ROB-FIN, 765 patients were
included in this study, of which 668, 256, and 66 initiated TNF-
inhibitors as their first, second, and third bDMARD. The number of
included courses of treatment was 990 (Fig. 1). Baseline characteristics
of these patients are presented in Table 1. Adalimumab (40%) was the
most commonly used TNF-inhibitor in this study followed by etaner-
cept (37%), infliximab (14%), and golimumab (8.8%). More than half ofFig. 1. Flowchart on patient selection.the patients were male (52%) and the median age at inclusion was 50
years. Median DAS28 scores at baseline of the first or second and third
bDMARD combined were 3.1 and 2.6, respectively. DAS28 scores were
lower (2.4 vs. 3.3) among the patients who potentially were already
receiving bDMARD treatment at the first recorded visit in comparison
to those whowere not. Among patients who started their treatment in
2004, the median DAS28 was 4.4 while the corresponding value in
2014 was 2.2. Statistically significant differences between users of
different TNF-inhibitors were observed across all of the observed
disease-activity parameters, but not in age, sex, or time from diagnosis.
Methotrexate, sulfasalazine, leflunomide, and glucocorticoids
were used by 53%, 17%, 9.4%, and 29% of patients at baseline visit,
respectively. The proportion of patients on biologic monotherapy
at onset of their first or second and third bDMARD combined were
25% and 33%, respectively. The amount of missing data varied from
0% to 20% across the variables in the data set at baseline.
Respective proportions of patients lost to follow-up within 6, 12,
24, and 36 months of treatment onset were 22%, 28%, 38%, and
44%, respectively. Median length of follow-up on TNF-inhibitor
treatments was 22.2 months.
Treatment response
Overall, 366 patients were excluded from effectiveness analyses
owing to the TNF-inhibitor being started before baseline assess-
ment. After 6 months of treatment onset, 68% and 51% of the
patients using TNF-inhibitors as their first bDMARD reached at
least moderate EULAR and ACR20 treatment responses while 68%
were in DAS28 remission (Fig. 2). After LUNDEX-correction, how-
ever, these percentages decreased to 44%, 33%, and 44%. There
were no statistically significant differences in unadjusted response
rates between the different TNF-inhibitors. Treatment responses to
TNF-inhibitors used as the patients’ second or third bDMARD were
inferior compared to being used as the first bDMARD (Supplement
1). Treatment responses to TNF-inhibitors used as the patients’
first bDMARD stratified by different TNF-inhibiting agents
(Supplement 2) or co-therapies (Supplement 3) were similar.
In addition to TNF-inhibiting agent and the use of concomitant
csDMARDs and glucocorticoids, the covariates used in the adjusted
model were age, sequential count of bDMARD therapies physi-
cian’s and patients’ global assessments of disease activity, HAQ,
and DAS28 (Supplement 4). Adjusted ordinal logistic regression
analyses revealed no statistically significant differences between
the TNF-inhibitors in achieving ACR20, 50, or 70 response at
6 months with or without adjusting for confounding or patient
attrition (Fig. 3). Patients treated with MTX (pOR ¼ 1.2, 95% CI:
0.70–1.9) or other csDMARDs (pOR ¼ 1.1, 95% CI: 0.63–2.1) had
similar proportional odds of achieving treatment response, as the
ones on biologic monotherapy. The use of glucocorticoids was not
statistically significantly associated with improved treatment
response. None of the interactions tested were statistically sig-
nificant and were therefore excluded from the final models.
Drug survival
Within 3, 6, and 12 months of treatment onset, 45 (4.5%), 93
(9.4%), and 170 (17%) of the patients had discontinued their
treatment, respectively. Based on Kaplan–Meier survival analysis,
the probabilities of discontinuing TNF-inhibitor therapy within 3,
6, 12, 24, and 36 months were 4.9%, 10%, 20%, 28%, and 34%,
respectively (Table 2). These discontinuation probabilities were
quite similar between users of the first, second, or third bDMARD.
The final Cox PH model comprised TNF-inhibiting agent, use of
concomitant csDMARDs, and glucocorticoids, as well as the year of
treatment onset, sex, availability of a valid baseline visit, patient
global assessment of disease activity, and tender joint count (0–28)
Fig. 2. Treatment responses and remission rates of TNF-inhibitors used as the patients’ first bDMARD therapy at 3, 6, 12, and 24 months within treatment onset.
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0.44–0.87) was superior to infliximab in drug survival while
etanercept (HR ¼ 0.77, 95% CI: 0.55–1.1) and golimumab (HR ¼0.75, 95% CI: 0.46–1.2) did not differ from it (Fig. 4). The hazards
did not remain constant for the duration of the follow-up. Within
the first 6 months of follow-up, HRs for adalimumab, etanercept,
Fig. 3. The results of ordinal logistic regression analyses on reaching ACR treatment response at 6 months on TNF-inhibitors used as the patients first, second, or third
bDMARD either excluding or including patients having discontinued the treatment or lost to follow-up. Additional model results are presented in Supplement 4.
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5.97), and 2.17 (95% CI: 0.39–12.20), respectively, while the
corresponding figures were 0.50 (95% CI: 0.34–0.74), 0.54 (95%
CI: 0.36–0.81), and 0.41 (95% CI: 0.21–0.81) for the remaining
period, respectively. Neither MTX (HR ¼ 0.82, 95% CI: 0.61–1.1) nor
other csDMARDs (HR ¼ 0.86, 95% CI: 0.59–1.2) differed from
biologic monotherapy in drug survival, but the use of glucocorti-
coids was associated with poorer treatment persistence (HR ¼ 1.7,
95% CI 1.3–2.2). The interactions between TNF-inhibitors and theTable 2
Discontinuation proportions of TNF-inhibitors
3 Months 6 Months
TNF-inhibitors used as the first bDMARD %, (95% CI)
Adalimumab 1.9 (0.11–3.7) 7.8 (4.2–11)
Etanercept 5.2 (2.3–8.0) 9.5 (5.6–13)
Golimumab 9.4 (0–19) 13 (0.24–24)
Infliximab 5.2 (0.93–9.2) 9.2 (3.6–15)
Total 4.1 (2.5–5.7) 9.0 (6.6–11)
TNF-inhibitors used as the second or third bDMARD %, (95% CI)
Adalimumab 2.4 (0–5.1) 8.3 (3.2–13)
Etanercept 11 (4.5–17) 17 (9.5–25)
Golimumab 12 (1.5–21) 24 (9.9–36)
Infliximab 0 (0–0) 0 (0–0)
Total 6.5 (3.6–9.3) 13 (9.3–17)
TNF-inhibitors uses as the first, second, or third bDMARD, (95% CI)
Adalimumab 2.1 (0.58–3.6) 8.0 (5.1–11)
Etanercept 6.8 (4.0–9.4) 12 (8.3–15)
Golimumab 11 (3.4–17) 19 (9.6–28)
Infliximab 4.5 (0.80–8.0) 8.0 (3.1–13)
Total 4.9 (3.5–6.3) 10 (8.3–12)use of csDMARDs or glucocorticoids were not statistically signifi-
cant, and hence, excluded from the final model.Discussion
This present study updates previous findings on TNF-inhibitor
treatment among PsA patients based on the ROB-FIN register with
extended follow-up and additional analyses on treatment response12 Months 24 Months 36 Months
16 (11–20) 24 (17–29) 29 (22–35)
15 (10–20) 24 (18–29) 30 (23–36)
26 (8.8–40) 26 (8.8–40) 26 (8.8–40)
27 (18–35) 43 (32–52) 48 (37–57)
18 (15–21) 27 (24–31) 33 (29–37)
17 (10–24) 25 (16–33) 31 (21–39)
28 (18–36) 35 (24–44) 39 (28–49)
35 (18–48) 38 (20–51) 45 (26–60)
21 (0–40) 37 (4.8–58) 37 (4.8–58)
24 (19–29) 31 (25–36) 36 (30–42)
16 (12–20) 24 (19–29) 30 (24–35)
19 (15–23) 27 (22–32) 33 (27–38)
31 (19–41) 33 (21–43) 37 (24–48)
26 (18–33) 42 (32–51) 46 (36–55)
20 (17–23) 28 (25–32) 34 (30–37)
Fig. 4. The results of a Cox proportional hazards model on the discontinuation of TNF-inhibitor therapy within 36 months of treatment onset. Additional model results are
presented in Supplement 4.
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subject exists, our study is the first to include golimumab. Our
findings are based on real-world evidence and are therefore
invaluable to supplement the results of randomized controlled
trials, whose stringent inclusion criteria and often brief follow-up
time limit their generalizability.Patients and methods
Inclusion and exclusion criteria were driven by both the
availability of data and our efforts to ensure the validity of the
study. DAS28 scores were included in the ROB-FIN starting from
2004, prohibiting the use of older data. The decision to exclude
patients with prior biologic treatment from effectiveness analyses
was due to our assumption that exposure to biologics would
confound baseline disease activity, which is crucial for valid
calculation of treatment responses. For drug survival analyses,
we included all patients but used an indicator of validity of the
baseline measurement as a potential confounding variable,
although it was excluded from the final model owing to insuffi-
cient explanatory value. Only infliximab, etanercept, adalimumab,
and golimumab were included in this study because the number of
patients using certolizumab pegol was very low owing to the lack
of marketing authorization. Golimumab did not enter clinical use
until 2010, and hence, the median year of treatment onset among
patients using it was later as compared to patients on other
included TNF-inhibitors. Requirement for a valid follow-up visit
was necessary for effectiveness analyses as otherwise any change
in disease activity would have been impossible to detect. In
sensitivity analyses, however, patients who discontinued their
treatment or were lost to follow-up were included as non-
responders regardless of whether or not they had any successive
visits to baseline.
This Finnish cohort differs in some areas from observational
studies previously reported. A DAS28 score as high as 6.4 was
observed in a study based on a British population while Danish
and Swedish studies reported median DAS28 scores of 4.8 and 4.9,
respectively [3,4,8]. In our population, median DAS28 was 2.9,indicating less severe or better managed disease as compared to
these previous studies. In fact, our data showed a significant
reduction in disease activity over time among patients starting
their biologic treatment. Also, some of the included patients may
have already been receiving treatment at their first recorded visit.
Penetration of MTX use was nevertheless similar between our
study and previous ones. Owing to differences in healthcare
practices and guidelines between countries, caution is required
when generalizing these findings outside Finland.
Treatment response
Good or moderate EULAR response after 6 months of treatment
onset was reached in 68% of the patients, which is less than 75%
and 91% reported in previous studies [4,8]. However, the results of
observational studies may not be fully comparable owing to the
differences in data collection routines, healthcare settings, and
national treatment guidelines between countries [17]. TNF-
inhibitors were found to be equipotent in effectiveness with and
without adjusting for potential confounding. Similarly, neither
MTX-based nor non-MTX-based csDMARD combinations were
associated with improved treatment response. Similar results have
been observed in previous studies [8,10].
Drug survival
In previous studies, 12–30% of patients have discontinued their
treatment within 1 year and 19–43% within 2 years of follow-up
[3,6,7,9]. Our respective results of 20% and 28% serve as a
confirmation to these previous findings. Our results suggested
that the hazard for discontinuing TNF-inhibitor therapy did not
differ between TNF-inhibitors during the first 6 months, but from
that point onward, infliximab was significantly inferior in terms of
drug survival in comparison to adalimumab, etanercept, or goli-
mumab. Infliximab has been linked to inferior drug survival
previously [3], yet prior studies have not reported results sepa-
rately for different time periods. Based on a meta-analysis of
randomized controlled trials, short-term safety and effectiveness
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ation to our findings [18]. The difference in drug survival and also
the non-proportional hazards might arise from the fact that
infliximab is administered intravenously and thus is covered by
the hospital budget instead of reimbursed by the National Insur-
ance Institution, which is the case with other TNF-inhibitors.
Although the majority of expenses are ultimately covered by
society in both the cases, hospitals may have sought to discontinue
infusion treatments in favor of self-administered ones to save
money. This trend was however absent in a related study among
patients with ankylosing spondylitis [19]. In any case, the HRs
considering TNF-inhibitors reported in Figure 3 should be inter-
preted as averages over time as hazards do not remain propor-
tional to each other for the entire duration of the follow-up period.
Concomitant use of MTX or other csDMARDs was not statistically
significantly associated with improved drug survival in our data
whereas some prior studies have found MTX improving treatment
persistence [3,4,10]. Our finding on glucocorticoids being associ-
ated with poorer drug survival could be a sign of residual
confounding as the need to use glucocorticoids often arises from
poorer response to TNF-inhibitors, which actually might be the
main reason for treatment discontinuation.
Limitations of the study
There were some limitations in this study. Within 36 months of
treatment onset, 45% of patients had been lost to follow-up. In the
effectiveness analyses, we explored the effect of patient attrition
using LUNDEX-correction and equivalent adjustment to ordinal
logistic regression. However, survival analyses assume non-
informative censoring, or in other words, that the patients lost to
follow-up do not differ from the ones remaining on treatment or
discontinuing it in a manner that would introduce bias to results.
Data were collected as a part of a tightly scheduled routine care,
and as a result, some data are missing. We assumed that data were
missing at random and imputed the missing values using multiple
imputations. Although ROB-FIN fails to cover 100% of bDMARD
therapies in Finland, we do not have any reason to suspect
systematic error to the results as a consequence. Regretfully, we
were unable to analyze the reasons for TNF-inhibitor discontinua-
tion as this information was too infrequently reported. In the
absence of more accurate comorbidity data, we used hospital
treatments and outpatient visits to specialized healthcare as
summary measures for them. The downside of this approach
was that comorbidities treated in community health centers such
as high blood pressure could not be accounted for. Outpatient
visits due to rheumatic diseases were ignored as bDMARDs are
currently only prescribed for PsA patients treated within speci-
alized healthcare. The joint count used in our data fell short of the
full 66/68 joint counts traditionally used in calculation of ACR
responses. As the ACR responses measure a proportional reduction
in the number of swollen and tender joints rather than an absolute
one, calculation of ACR response was possible with the joint counts
available to us. However, we cannot ascertain if the responses
would be exactly similar in case of a full 66/68 joint count could
have been used instead.Conclusion
In this study, we found that 68% and 51% of PsA patients treated
with TNF-inhibitors as their first bDMARD reached at least
moderate EULAR and ACR20 response after 6 months of treatment
onset, respectively. We found signs of concomitant csDMARD
therapy improving treatment response and drug survival,
but these findings were not statistically significant. DifferentTNF-inhibitors were mostly equipotent in effectiveness, but treat-
ment persistence on infliximab was inferior as compared to other
TNF-inhibitors, especially after 6 months of treatment onset.Ackowledgments
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